The Cooper Companies, Inc (COO) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of The Cooper Companies, Inc stock $70.86, price $63.51, upside +11.6%, quality 62 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
The stock costs 10% less than our calculation considers fair.
Fair value $70.86 · Undervalued (10%)
Quality 62/100
Healthy Growth(revenue 5y +11.0 %/yr in USD)
Solidly profitable · 13.5% net margin (TTM)
Low debt
Generates free cash flow
Mixed vs. peers(7/14)
Moderate moat53/100 · thin data
Insiders bought $1.9M (6M)
Some data
Wide range: only $35.57 in the cautious scenario.
Negative coverage
Quality growth
Risks from the AI analysis
🚩Price drop: Channel inventory normalization pressuring reported sales🚩Larger rivals like J&J and Alcon could erode share🚩DTC and e-commerce could commoditise standard lenses
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $53.27 – $113.94 · fair‑value band $35.57 – $88.59 · the $63.51 price screens below the $70.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow The Cooper Companies in your weekly email
Every Wednesday you see whether The Cooper Companies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical.
Show moreShow less
The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia.
Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.
This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing.
The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers.
The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Stock analysis
The Cooper Companies, Inc (COO) currently trades at $63.51, while our model-based Fair Value estimate is $70.86, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $44.25 per share, and 4 of the 24 models we run sit above the $63.51 price.
Bear case: the Asset-Based group reads lowest at $9.86, and 20 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $35.57 (bear) to $88.59 (bull), the price of $63.51 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
The Cooper Companies, Inc reported revenue of $4.1B in FY2025 versus $2.9B in FY2021, a compound +8.8%/yr. Reported net income was $375M in FY2025, compounding −40.3%/yr from FY2021.
Key figures
Market cap $12.3B Large · P/E ratio 21.8 · P/S ratio 2.90 · EPS (TTM) $2.91 · Net margin 13.5% · Return on equity 6.8% · Return on assets (EBIT) 5.1% · Operating margin 20.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 25% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at 12%, COO screens cheaper than that median.
Fair Value models
Bear$35.57Fair Value $70.86Bull$88.59
Price $63.51 · Upside +11.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($2.91 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors bought shares worth $1.9M, most recently on Sep 16, 2026. Buying cluster
BuyLawrence Erik KurziusDirector3× since Dec 17, 2025: 22,000 shares, avg. $56.98$1.3MSep 16, 2026
BuyWalter M Rosebrough JrDirector10,000 shares at $54.16$541,640Sep 14, 2026
BuyPaul A KeelDirector4,701 shares at $53.18$250,000Sep 11, 2026
BuyCynthia L LuccheseDirector1,784 shares at $84.06$149,963Dec 22, 2025
BuyMaria RivasDirector1,000 shares at $82.13$82,130Dec 18, 2025
BuyAlbert G White IIIPresident & CEO, Director10,000 shares at $80.80$808,000Dec 16, 2025
BuyHolly R SheffieldPresident, CSI1,230 shares at $80.75$99,323Dec 16, 2025
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +8.6% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+0.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.3% vs 3.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.1% a year for the price and +1.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: Solid gross margins stand as the main strength, yet low return on equity relative to margins remains the clearest weakness in business quality.
Main risk: Named competitors such as Johnson & Johnson Vision and Alcon might capture more customers with broader portfolios or advanced surfaces, pressuring CooperVision's prices and margins in the contact lens market.
Bull case: By accelerating its pipeline of specialty lenses such as MiSight for myopia control and leveraging the new innovation hub, the company could strengthen its position against rivals and sustain premium pricing.
Bear case: If larger competitors expand their parameter ranges and marketing, CooperVision might lose share in key segments, leading to slower growth and margin compression in its core contact lens business.
CooperVision faces US channel inventory normalization that continues to pressure reported sales even as premium offerings like MiSight deliver solid organic growth. Record free cash flow supports expanded buybacks after the strategic review kept CooperSurgical, yet activist pressure for leadership shifts adds uncertainty. Will the underlying demand and product momentum overcome the reset effects, or will channel dynamics weigh on results longer than anticipated?
Compare The Cooper Companies, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+11.6% · Above median
Profitability
Return on equity (12 months)6.8% · Below median
Return on assets3.0% · Below median
Net margin (12 months)13.5% · Above median
Operating margin (12 months)20.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)0.6% · Below median
Balance sheet
Debt / equity0.30× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "The Cooper Companies, Inc Fair Value". https://www.fairvalue-calculator.com/stock/COO
Frequently asked questions
Is The Cooper Companies, Inc (COO) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $70.86 versus a price of $63.51, about +12% upside (undervalued).
What is the fair value of COO?
Our model-based fair value for The Cooper Companies, Inc is $70.86 (as of Nov 5, 2026), built from audited fundamentals. The current price: $63.51.
What is the quality score of COO?
The Cooper Companies, Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for The Cooper Companies, Inc (COO)?
Our model-based price target is the fair value of $70.86 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $35.57, optimistic scenario $88.59. It is a calculation from audited fundamentals, not an analyst target.
What is the The Cooper Companies, Inc stock forecast for 2026?
Our models put fair value at $70.86, about +12% upside versus a price of $63.51 (undervalued). Cautious scenario $35.57, optimistic scenario $88.59. The calculation is refreshed regularly with new filings.
What is the revenue of The Cooper Companies, Inc (COO)?
The Cooper Companies, Inc reported trailing-twelve-month revenue of about $4.2B (latest available figure, as of Nov 5, 2026).
What growth is priced into The Cooper Companies, Inc (COO)?
For today's price to be fair in a discounted-cash-flow model, The Cooper Companies, Inc would have to grow free cash flow by +16.8 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of COO use?
Our models discount The Cooper Companies, Inc at 8.8 %: a base by market capitalisation (large), damped by beta 0.83, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For The Cooper Companies, Inc that is +16.8 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has The Cooper Companies, Inc (COO) delivered so far?
Over the past 5 years revenue at The Cooper Companies, Inc grew +11.0 % a year. The price currently implies +16.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of The Cooper Companies, Inc (COO) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into The Cooper Companies, Inc (+16.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of The Cooper Companies, Inc (COO)?
The free-cash-flow yield on the price is 3.53 %: that much free cash flow The Cooper Companies, Inc produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of The Cooper Companies, Inc (COO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For The Cooper Companies, Inc it is $70.86 per share (as of Nov 5, 2026), against a price of $63.51. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is The Cooper Companies, Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, COO trades below its calculated fair value: price $63.51, fair value $70.86, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COO?
No. The price is what the market pays today ($63.51); the fair value is what the company's own numbers justify ($70.86). For The Cooper Companies, Inc the two are $7.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is The Cooper Companies, Inc worth?
The market values The Cooper Companies, Inc at about $12.3B (market capitalisation, as of Nov 5, 2026). Per share that is $63.51; our models calculate a fair value of $70.86 per share.
What do the bullish and bearish scenarios say about COO?
Our models span a range for The Cooper Companies, Inc: cautious scenario $35.57, base $70.86, optimistic $88.59 per share (as of Nov 5, 2026, price $63.51). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of COO?
The Cooper Companies, Inc trades at a price-to-earnings ratio of 21.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $70.86 is built from several models across several years. Other multiples: PEG 0.5, P/B 1.5, P/S 2.9, EV/EBITDA 15.7.
What is the PEG ratio of COO?
The PEG ratio of The Cooper Companies, Inc is 0.52 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of The Cooper Companies, Inc (COO)?
Balance-sheet figures for The Cooper Companies, Inc (as of Nov 5, 2026): return on equity 6.8%, debt of 0.30 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is COO from its 52-week high?
The Cooper Companies, Inc trades at $63.51, about 25% below its 52-week high of $84.32 and 19% above the low of $53.27 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $70.86 is for.
Which stocks are comparable to The Cooper Companies, Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is The Cooper Companies, Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $63.51, calculated fair value $70.86 (+12%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COO calculated?
We run The Cooper Companies, Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $70.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. The Cooper Companies, Inc currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of The Cooper Companies, Inc (COO)?
The closing price on Nov 5, 2026 was $63.51. Our model-based fair value is $70.86, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with The Cooper Companies, Inc right now?
A fairly wide model range ($35.57 to $88.59) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of The Cooper Companies, Inc (COO) come from?
Earnings per share at The Cooper Companies, Inc grew +3.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.4 %, EBIT margin +0.5 %, tax rate −3.4 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of The Cooper Companies, Inc
How large is the market capitalisation of The Cooper Companies, Inc (COO)?
The market capitalisation of The Cooper Companies, Inc is $12.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of The Cooper Companies, Inc (COO)?
The price-to-sales ratio of The Cooper Companies, Inc is 2.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of The Cooper Companies, Inc (COO)?
Earnings per share at The Cooper Companies, Inc are $2.91 (price ÷ EPS = P/E 21.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of The Cooper Companies, Inc (COO)?
The net margin of The Cooper Companies, Inc is 13.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of The Cooper Companies, Inc (COO)?
The return on equity (ROE) of The Cooper Companies, Inc is 6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of The Cooper Companies, Inc (COO)?
On an EBIT basis the return on assets of The Cooper Companies, Inc is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of The Cooper Companies, Inc (COO)?
The operating margin of The Cooper Companies, Inc is 20.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at The Cooper Companies, Inc (COO)?
Revenue at The Cooper Companies, Inc is growing +0.6% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at The Cooper Companies, Inc (COO)?
Earnings per share at The Cooper Companies, Inc are growing +357% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does The Cooper Companies, Inc (COO) carry?
The net debt of The Cooper Companies, Inc is $2.7B (fiscal year 2025, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch The Cooper Companies, Inc in the live analysis
One click puts The Cooper Companies, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026